Market Trends of Cardiac Arrhythmia Therapeutics Industry
This section covers the major market trends shaping the Cardiac Arrhythmia Therapeutics Market according to our research experts:
Sodium-channel Blockers Segment is Expected to Hold a Major Market Share in the Cardiac Arrhythmia Therapeutics Market
- Sodium channel blockers are class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of Sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability and conduction velocity. These blockers are used for the treatment of atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, symptomatic ventricular premature beats, and prevention of ventricular fibrillation.
- According to the Centers for Disease Control and Prevention (CDC), estimates approximately 2 percent of people younger than 65 years old have atrial fibrillation, while about 9 percent of people ages 65 and older have it. Moreover, in the United States, prevalence rate of atrial fibrillation is estimated to rise to 12.1 million by the year 2030.
- Sodium-channel blockers segment holds a significant market share in the cardiac arrhythmia therapeutics market and is anticipated to show similar trend over the forecast period due to easy to consume, no pain, low cost and extended-release effect of drugs.
- Increasing incidences of chronic diseases worldwide, technological advancements and growing awareness regarding early diagnosis of diseases are the key driving factors in the sodium-channel blockers segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global cardiac arrhythmia therapeuticsmarketdue to increasing geriatric population, high drug consumption & costs, and growing incidence of cardiac diseases.Centers for Disease Control and Prevention, estimates approximately 2.7 million and 6.1 million people in the United States have atrial fibrillation. In addition, in the year 2017, atrial fibrillation was responsible for 26,077 deaths in the United States. Furthermore, presence of top pharma and biotech companies, increasing healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.